Affibody AB and GE Healthcare Enter a Research Agreement
Affibody® molecules, with their favorable biodistribution, high target specificity and acceptability to protein engineering approaches, are considered suitable candidates for targeted in vivo imaging applications. The aim is to allow early diagnosis of disease and thereby allowing physicians to optimize the therapy on a personalized basis. Under the agreement, GE Healthcare has the exclusive option to take any licenses required for developing and commercializing imaging agents resulting from this collaboration. Affibody retains all rights for use of the selected Affibody® molecules outside the scope of in vivo diagnostic and medical imaging.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.